JP3023987B2 - （Ｓ）−α−フェニル−２−ピリジンエタンアミン（Ｓ）−マレートおよび医薬としてのその使用 - Google Patents

（Ｓ）−α−フェニル−２−ピリジンエタンアミン（Ｓ）−マレートおよび医薬としてのその使用

Info

Publication number
JP3023987B2
JP3023987B2 JP6521814A JP52181494A JP3023987B2 JP 3023987 B2 JP3023987 B2 JP 3023987B2 JP 6521814 A JP6521814 A JP 6521814A JP 52181494 A JP52181494 A JP 52181494A JP 3023987 B2 JP3023987 B2 JP 3023987B2
Authority
JP
Japan
Prior art keywords
phenyl
pyridineethanamine
malate
compound
enantiomeric purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP6521814A
Other languages
English (en)
Japanese (ja)
Other versions
JPH08508292A (ja
Inventor
マリー，ロバート・ジヨン
マシセン，ドナルド
バーレストラ，マイケル
Original Assignee
アストラ・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1993/000689 external-priority patent/WO1993020052A1/en
Application filed by アストラ・アクチエボラーグ filed Critical アストラ・アクチエボラーグ
Publication of JPH08508292A publication Critical patent/JPH08508292A/ja
Application granted granted Critical
Publication of JP3023987B2 publication Critical patent/JP3023987B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP6521814A 1993-04-01 1994-03-29 （Ｓ）−α−フェニル−２−ピリジンエタンアミン（Ｓ）−マレートおよび医薬としてのその使用 Expired - Lifetime JP3023987B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
GB9320273.7 1993-10-01
GB93/00689 1993-10-01
GB939320273A GB9320273D0 (en) 1993-04-01 1993-10-01 Compound useful in therapy
PCT/GB1994/000651 WO1994022831A1 (en) 1993-04-01 1994-03-29 (s)-alpha-phenyl-2-pyridineethanamine (s)-malate and its use as a medicament

Publications (2)

Publication Number Publication Date
JPH08508292A JPH08508292A (ja) 1996-09-03
JP3023987B2 true JP3023987B2 (ja) 2000-03-21

Family

ID=26302299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6521814A Expired - Lifetime JP3023987B2 (ja) 1993-04-01 1994-03-29 （Ｓ）−α−フェニル−２−ピリジンエタンアミン（Ｓ）−マレートおよび医薬としてのその使用

Country Status (19)

Country Link
EP (1) EP0691957B1 (no)
JP (1) JP3023987B2 (no)
CN (1) CN1047168C (no)
AT (1) ATE156813T1 (no)
AU (1) AU682348B2 (no)
CA (1) CA2159478C (no)
DE (1) DE69404974T2 (no)
DK (1) DK0691957T3 (no)
DZ (1) DZ1765A1 (no)
ES (1) ES2105672T3 (no)
FI (1) FI109018B (no)
GB (1) GB9320273D0 (no)
GR (1) GR3025081T3 (no)
IL (1) IL109108A (no)
MA (1) MA23154A1 (no)
NO (1) NO304647B1 (no)
PH (1) PH30950A (no)
SG (1) SG48204A1 (no)
WO (1) WO1994022831A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135206T1 (de) * 1988-08-12 1996-03-15 Astra Ab Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901340D0 (sv) * 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
SE9901338D0 (sv) * 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
DE10301650A1 (de) * 2003-01-17 2004-07-29 Johannes-Gutenberg-Universität Mainz Medizinisch nützliche 1-Phenyl-2-aminomethylnaphthaline, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und deren Verwendung
EP2391606A4 (en) 2008-12-24 2012-06-13 Astrazeneca Ab ETHANAMINE COMPOUNDS AND THEIR APPLICATION FOR THE TREATMENT OF DEPRESSION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) * 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
WO1993020052A1 (en) * 1992-04-03 1993-10-14 Fisons Corporation Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
ATE135206T1 (de) * 1988-08-12 1996-03-15 Astra Ab Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung
JP2514855B2 (ja) * 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩

Also Published As

Publication number Publication date
NO953846L (no) 1995-11-21
GR3025081T3 (en) 1998-01-30
CA2159478A1 (en) 1994-10-13
AU6380294A (en) 1994-10-24
ATE156813T1 (de) 1997-08-15
WO1994022831A1 (en) 1994-10-13
DE69404974T2 (de) 1997-12-18
FI109018B (fi) 2002-05-15
GB9320273D0 (en) 1993-11-17
DK0691957T3 (da) 1997-10-27
CA2159478C (en) 2005-01-25
CN1047168C (zh) 1999-12-08
EP0691957A1 (en) 1996-01-17
JPH08508292A (ja) 1996-09-03
EP0691957B1 (en) 1997-08-13
AU682348B2 (en) 1997-10-02
CN1098095A (zh) 1995-02-01
IL109108A (en) 1999-01-26
SG48204A1 (en) 1998-04-17
DE69404974D1 (de) 1997-09-18
IL109108A0 (en) 1994-06-24
FI954645A0 (fi) 1995-09-29
PH30950A (en) 1997-12-23
DZ1765A1 (fr) 2002-02-17
MA23154A1 (fr) 1994-12-31
NO953846D0 (no) 1995-09-28
NO304647B1 (no) 1999-01-25
ES2105672T3 (es) 1997-10-16
FI954645A (fi) 1995-11-29

Similar Documents

Publication Publication Date Title
US6242462B1 (en) Pharmacological agents
EP0633879B1 (en) Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
JP3023987B2 (ja) （Ｓ）−α−フェニル−２−ピリジンエタンアミン（Ｓ）−マレートおよび医薬としてのその使用
KR102269493B1 (ko) (r)-디미라세탐 (1) 및 (s)-디미라세탐 (2)을 비-라세미 비로 포함하는 상승작용적 조성물
US5455259A (en) Compounds for the treatment of neurodegenerative disorders
JP3023988B2 (ja) （Ｓ）−α−フェニル−２−ピリジンエタンアミンベンゾエートおよび医薬としてのその使用
TW201105324A (en) 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives
JP2012532855A (ja) 医薬として使用するための組合せ製剤
AU639722B2 (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
CN105792821A (zh) 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂
WO2012033435A1 (ru) Способ, соединение, фармацевтическая композиция и лекарственное средство для восстановления утраченной памяти в норме и патологии
US20080081926A1 (en) Sulfonylaminobenzoic acid and salt
WO2012030258A1 (ru) Гетероциклические низкомолекулярные sapp-миметики, фармацевтическая композиция, способы получения и применения
TW390875B (en) (S) -<alpha>-phenyl-2-pyridineethanamine (S)-malate useful in therary, its perparing process and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080121

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090121

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100121

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110121

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120121

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130121

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130121

Year of fee payment: 13

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term